Pharma Momentum Fuels Johnson & Johnson's Path to Double-Digit Upside

Johnson & Johnson’s pharma momentum is supporting a fresh Wall Street upside view, with a 24/7 Wall St. price target of $261.72 versus a $235.18 share level, implying 11.28% upside. The firm reiterates a buy stance with a 90% confidence level. The article highlights recent Q1 2026 results, including revenue rising 9.9% to $24.062 billion and adjusted EPS of $2.70, which beat estimates for the fourth straight quarter. Management raised 2026 guidance to $100.3B–$101.3B in sales and $11.45–$11.65 in adjusted EPS, citing catalysts such as a $1 billion Vision manufacturing expansion in Jacksonville and the $1 billion Firefly Bio acquisition. It also points to Talvey, showing up to a 53% mortality risk reduction in multiple myeloma. Risks cited include STELARA’s 59.7% Q1 decline, $330 million in Q1 litigation charges, and remaining talc-case overhang, with a bear-case target of $222.46.